| Literature DB >> 26445099 |
Milan Blaha1, Lucie Nemcova1, Katerina Vodickova Kepkova1, Petr Vodicka2, Radek Prochazka3.
Abstract
BACKGROUND: The gonadotropin-induced resumption of oocyte meiosis in preovulatory follicles is preceded by expression of epidermal growth factor (EGF)-like peptides, amphiregulin (AREG) and epiregulin (EREG), in mural granulosa and cumulus cells. Both the gonadotropins and the EGF-like peptides possess the capacity to stimulate resumption of oocyte meiosis in vitro via activation of a broad signaling network in cumulus cells. To better understand the rapid genomic actions of gonadotropins (FSH) and EGF-like peptides, we analyzed transcriptomes of cumulus cells at 3 h after their stimulation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26445099 PMCID: PMC4596359 DOI: 10.1186/s12958-015-0112-2
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1Design of hybridization scheme of microarray experiment. Each arrow represents one microarray. Samples of cumulus cells stimulated with AREG/EREG, FSH or control cells were labeled with AlexaFluor 555 (depicted in green) or AlexaFluor 647 (depicted in red)
Fig. 2Venn diagrams summarizing microarray data analysis. a Venn diagram showing numbers of overexpressed and (b) underexpressed genes in cumulus cells after stimulation of COCs with FSH or AREG/EREG. Only genes with log2 fold-change above 1.5 were considered for this analysis
Fig. 3Functional classification and numbers of genes over- and underexpressed in cumulus cells after stimulation with FSH (a) or AREG/EREG (b). Only genes with log2 fold-change above 1.5 were considered for this analysis. The numbers of genes affected by the treatments are shown at the top of the panels. The gene ontology analysis was performed using DAVID Bioinformatic Resources (http://david.abcc.ncifcrf.gov/)
Verification of selected differentially expressed genes by real time RT-PCR
| Probe name | Gene symbol | Gene description | Fold change in gene expression values determined by RT-PCR (Mean ± SEM) | Significance vs. non-stimulated control | Array results (Fold change) |
|---|---|---|---|---|---|
| FSH vs. Control - overexpressed | |||||
| 31605:45360_15417313:f |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 5 | 0.83 ± 0.12 | ns. | 4.79 |
| 9436:30168_CL9Contig1:f |
| ADAM metallopeptidase with thrombospondin type 1 motif, 1 | 3.72 ± 0.36 | *** | 6.95 |
| 13062:45360_CL23Contig1:f |
| Annexun A1 | 0.93 ± 0.10 | ns. | 3.15 |
| 1117:45360_CL10Contig1:r |
| Annexin A2 | 0.98 ± 0.07 | ns. | 4.02 |
| 14127:9388_21549088:r |
| Amphiregulin | 5.04 ± 0.46 | *** | 4.06 |
| 18133:7423_CL1Contig2:r |
| CCAAT/enhancer binding protein (C/EBP), beta | 9.68 ± 1.58 | *** | 2.89 |
| 6532:35657_CL1Contig1:r |
| Cytochrome P450, family 11, subfamily A, polypeptide 1 | 11.92 ± 0.90 | *** | 16.20 |
| TC226972:f |
| Forkhead box O3 | 1.97 ± 0.21 | ** | 4.22 |
| TC235800:f |
| Hyaluronan synthase 2 | 47.63 ± 5.11 | *** | 6.59 |
| 9355:35407_CL1Contig1:f |
| Hydroxysteroid (17-beta) dehydrogenase 7 | 3.35 ± 0.30 | *** | 3.87 |
| 5795:24780_CL1Contig1:r |
| MARCKS-like 1 | 4.44 ± 0.53 | *** | 2.85 |
| 1337:12192_CL1Contig2:f |
| Ornithine decarboxylase 1 | 6.22 ± 0.85 | ** | 5.26 |
| 15979:340_CL1Contig1:f |
| Pre-B-cell leukemia homeobox 1 | 0.70 ± 0.10 | * | 4.24 |
| 31453:2453_233792:f |
| Progesterone receptor | 23.99 ± 5.10 | ** | 15.57 |
| 8538:3878_CL2Contig1:f |
| Plasminogen activator, tissue | 14.16 ± 2.36 | *** | 5.48 |
| 4143:1539_CL1Contig1:r |
| Plasminogen activator, urokinase receptor | 2.56 ± 0.20 | *** | 4.00 |
| 33691:1766_29276590:r |
| Peroxiredoxin 2 | 6.30 ± 0.44 | *** | 2.88 |
| 13439:18092_CL1Contig1:r |
| Ribokinase | 0.51 ± 0.07 | *** | 7.32 |
| 3373:854_CL1Contig1:f |
| Regulator of G-protein signaling 2 | 3.47 ± 0.77 | * | 3.13 |
| 33911:29637_CL1Contig1:r |
| Suprabasin | 20.37 ± 1.56 | *** | 21.54 |
| TC204140:f |
| Syndecan 1 | 2.55 ± 0.57 | * | 13.44 |
| 2269:10415_CL1Contig1:f |
| Syndecan 4 | 13.79 ± 1.71 | *** | 6.29 |
| TC238171:f |
| Serpin peptidase inhibitor, clade E, member 1 | 3.05 ± 0.50 | * | 14.47 |
| 31918:32605_CL1Contig2:f |
| Spermine oxidase | 33.26 ± 7.94 | ** | 6.29 |
| 5977:12455_CL1Contig1:r |
| Tumor necrosis factor alpha-induced protein 6 | 2517 ± 105 | *** | 30.54 |
| 19103:6332_CL1Contig1:f |
| Tumor necrosis factor receptor superfamily, member 12A | 0.52 ± 0.17 | * | 3.04 |
| 9402:4028_CL1Contig1:r |
| UDP-N-acetylglucosamine pyrophosphorylase 1 | 8.01 ± 1.11 | *** | 5.71 |
| FSH vs. Control - underexpressed | |||||
| 707:4250_CL1Contig1:f |
| Proto-oncogene protein c-fos | 8.56 ± 2.43 | * | 0.15 |
| 1893:12937_CL1Contig1:f |
| Forkhead box O1 | 0.90 ± 0.09 | ns. | 0.29 |
| 6206:5117_CL1Contig1:f |
| Follistatin | 0.21 ± 0.02 | *** | 0.10 |
| 15012:1275_CL1Contig1:f |
| Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 | 0.80 ± 0.12 | ns. | 0.32 |
| TC210305:f |
| Insulin receptor substrate 1 | 0.98 ± 0.25 | ns. | 0.14 |
| NM_213880.1 |
| Jun proto-oncogene | 1.03 ± 0.14 | ns. | 0.06 |
| 2480:21101_CL1Contig1:f |
| Proliferating cell nuclear antigen | 1.16 ± 0.12 | ns. | 0.29 |
| 18375:27730_CL1Contig1:r |
| Proline-rich nuclear receptor coactivator 1 | 0.94 ± 0.15 | ns. | 0.21 |
| 14891:209_CL4Contig1:f |
| Peroxisome proliferator-activated receptor gamma | 0.45 ± 0.04 | *** | 0.32 |
| 1456:37319_CL1Contig1:f |
| Prostaglandin E synthase | 0.70 ± 0.10 | ** | 0.26 |
| 12586:12773_CL1Contig1:f |
| Regulator of G-protein signaling 3 | 0.78 ± 0.10 | * | 0.17 |
| TC229705:f |
| Tribbles pseudokinase 2 | 0.84 ± 0.10 | ns. | 0.33 |
| AREG/EREG vs. Control - overexpressed | |||||
| 13062:45360_CL23Contig1:f |
| Annexin A1 | 0.68 ± 0.11 | * | 3.68 |
| 1117:45360_CL10Contig1:r |
| Annexin A2 | 2.51 ± 0.41 | ** | 4.41 |
| 45:916_CL3Contig1:f |
| Connective tissue growth factor | 2.20 ± 0.25 | *** | 6.19 |
| 6532:35657_CL1Contig1:r |
| Cytochrome P450, family 11, subfamily A, polypeptide 1 | 2.68 ± 0.44 | ** | 5.82 |
| 14983:2713_CL1Contig1:f |
| Eukaryotic translation initiation factor 4E | 2.56 ± 0.72 | ns. | 4.14 |
| 977:13547_CL1Contig2:r |
| Inositol-trisphosphate 3-kinase A | 5.41 ± 1.22 | * | 3.36 |
| 5795:24780_CL1Contig1:r |
| MARCKS-like 1 | 4.96 ± 0.72 | *** | 3.41 |
| 31453:2453_233792:f |
| Progesterone receptor | 4.01 ± 0.58 | *** | 5.25 |
| 33911:29637_CL1Contig1:r |
| Suprabasin | 4.33 ± 0.40 | *** | 4.34 |
| TC204140:f |
| Syndecan 1 | 1.01 ± 0.01 | ns. | 5.88 |
| TC238171:f |
| Serpin peptidase inhibitor, clade E, member 1 | 6.73 ± 0.65 | *** | 33.82 |
| 19103:6332_CL1Contig1:f |
| Tumor necrosis factor receptor superfamily, member 12A | 4.34 ± 0.53 | ** | 7.70 |
| AREG/EREG vs. Control - underexpressed | |||||
| 707:4250_CL1Contig1:f |
| Proto-oncogene protein c-fos | 3.29 ± 0.57 | ** | 0.09 |
| 1893:12937_CL1Contig1:f |
| Forkhead box O1 | 1.06 ± 0.25 | ns. | 0.33 |
| 6206:5117_CL1Contig1:f |
| Follistatin | 1.01 ± 0.07 | ns. | 0.25 |
| 9260:5151_CL1Contig1:f |
| Growth arrest and DNA-damage-inducible, alpha | 1.20 ± 0.32 | ns. | 0.35 |
| 2134:17017_CL1Contig1:f |
| Inhibitor of DNA binding 1protein | 1.24 ± 0.16 | ns. | 0.31 |
| NM_213880.1 |
| Jun proto-oncogene | 0.54 ± 0.02 | *** | 0.04 |
| 30832:5168_40390252:f |
| Nuclear receptor subfamily 5, group A, member 2 | 1.06 ± 0.08 | ns. | 0.31 |
| 18375:27730_CL1Contig1:r |
| Proline-rich nuclear receptor coactivator 1 | 0.65 ± 0.16 | * | 0.32 |
| 3373:854_CL1Contig1:f |
| Regulator of G-protein signaling 2 | 1.29 ± 0.09 | ** | 0.34 |
| 12586:12773_CL1Contig1:f |
| Regulator of G-protein signaling 3 | 0.36 ± 0.03 | *** | 0.13 |
| TC229705:f |
| Tribbles pseudokinase 2 | 0.94 ± 0.11 | ns. | 0.77 |
ns. not significant. *P < 0.05; ** P < 0.01; *** P < 0.001
Fig. 4Quantitative real-time PCR validation of genes found to be overexpressed in AREG/EREG vs. FSH microarray. The relative abundance of specific gene mRNA is expressed in arbitrary units as fold increases in the specific gene /HPRT ratio over the level found in the control group at the time 0 h. C control, AE AREG/EREG, F FSH. P < 0.05 for single asterisk; P < 0.01 for double asterisk; P < 0.001 for triple asterisk
Fig. 5Quantitative real-time PCR validation of genes found to be underexpressed in AREG/EREG vs. FSH microarray. The relative abundance of specific gene mRNA is expressed in arbitrary units as fold increases in the specific gene /HPRT ratio over the level found in the control group at the time 0 h. C control, AE AREG/EREG, F FSH. P < 0.05 for single asterisk; P < 0.01 for double asterisk; P < 0.001 for triple asterisk
Fig. 6Expression of transcription factors in COCs cultured with AREG/EREG or FSH for various lengths of time. The relative abundance of specific gene mRNA is expressed in arbitrary units as fold increases in the specific gene /HPRT ratio over the level found in the control group of COCs at the time 0 h